122 related articles for article (PubMed ID: 9113085)
1. Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo.
Moorthy B; Sriram P; Randerath E; Randerath K
Biochem Pharmacol; 1997 Mar; 53(5):663-9. PubMed ID: 9113085
[TBL] [Abstract][Full Text] [Related]
2. Effects of cytochrome P450 inducers on I-compounds in rat liver and kidney DNA.
Li D; Moorthy B; Chen S; Randerath K
Carcinogenesis; 1992 Jul; 13(7):1191-8. PubMed ID: 1638686
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.
Randerath K; Moorthy B; Mabon N; Sriram P
Carcinogenesis; 1994 Oct; 15(10):2087-94. PubMed ID: 7955037
[TBL] [Abstract][Full Text] [Related]
4. Induction of tamoxifen-4-hydroxylation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), beta-naphthoflavone (beta NF), and phenobarbital (PB) in avian liver: identification of P450 TCDDAA as catalyst of 4-hydroxylation induced by TCDD and beta NF.
Kupfer D; Mani C; Lee CA; Rifkind AB
Cancer Res; 1994 Jun; 54(12):3140-4. PubMed ID: 8205532
[TBL] [Abstract][Full Text] [Related]
5. Sex-specific modulation of hepatic covalent DNA modifications (I-compounds) by the cytochrome P450 inducer, pregnenolone-16 alpha-carbonitrile.
Moorthy B; van Golen KL; Randerath K
Toxicol Appl Pharmacol; 1992 Apr; 113(2):218-26. PubMed ID: 1561630
[TBL] [Abstract][Full Text] [Related]
6. Effects of a single dose of the cytochrome P450 inducer, beta-naphthoflavone, on hepatic and renal covalent DNA modifications (I-compounds).
Moorthy B; Sriram P; Randerath K
Toxicology; 1995 Dec; 104(1-3):165-77. PubMed ID: 8560495
[TBL] [Abstract][Full Text] [Related]
7. Polycyclic aromatic hydrocarbon-inducible DNA adducts: evidence by 32P-postlabeling and use of knockout mice for Ah receptor-independent mechanisms of metabolic activation in vivo.
Kondraganti SR; Fernandez-Salguero P; Gonzalez FJ; Ramos KS; Jiang W; Moorthy B
Int J Cancer; 2003 Jan; 103(1):5-11. PubMed ID: 12455047
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a PCN-P450 enzyme in chickens and comparison of its development with that of other phenobarbital-inducible forms.
Lorr NA; Bloom SE; Park SS; Gelboin HV; Miller H; Friedman FK
Mol Pharmacol; 1989 May; 35(5):610-6. PubMed ID: 2725470
[TBL] [Abstract][Full Text] [Related]
9. Different profiles of hepatic alkoxyresorufin O-dealkylase activities in small rodents.
Chatuphonprasert W; Rermraksakul P; Udomsuk L; Lao-ong T; Jarukamjorn K
J Appl Toxicol; 2012 Dec; 32(12):1002-7. PubMed ID: 22610983
[TBL] [Abstract][Full Text] [Related]
10. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
11. Chemical structure- and time-dependent effects of polycyclic aromatic hydrocarbon-type inducers on rat liver cytochrome P450, DNA adducts, and I-compounds.
Moorthy B; Sriram P; Randerath K
Fundam Appl Toxicol; 1994 May; 22(4):549-60. PubMed ID: 8056202
[TBL] [Abstract][Full Text] [Related]
12. The model Ah-receptor agonist beta-naphthoflavone inhibits aflatoxin B1-DNA binding in vivo in rainbow trout at dietary levels that do not induce CYP1A enzymes.
Takahashi N; Harttig U; Williams DE; Bailey GS
Carcinogenesis; 1996 Jan; 17(1):79-87. PubMed ID: 8565141
[TBL] [Abstract][Full Text] [Related]
13. Pentachlorophenol enhances 9-hydroxybenzo [a] pyrene-induced hepatic DNA adduct formation in vivo and inhibits microsomal epoxide hydrolase and glutathione S-transferase activities in vitro: likely inhibition of epoxide detoxication by pentachlorophenol.
Moorthy B; Randerath K
Arch Toxicol; 1996; 70(11):696-703. PubMed ID: 8896715
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
15. Hepatic cytochrome P450 induction in goats. Effects of model inducers on the metabolism of alkoxyresorufins, testosterone and ethylmorphine, and on apoprotein and mRNA levels.
van't Klooster GA; Horbach GJ; Natsuhori M; Blaauboer BJ; Noordhoek J; van Miert AS
Biochem Pharmacol; 1993 Jan; 45(1):113-22. PubMed ID: 8424805
[TBL] [Abstract][Full Text] [Related]
16. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen.
Pathak DN; Pongracz K; Bodell WJ
Carcinogenesis; 1995 Jan; 16(1):11-5. PubMed ID: 7834794
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo.
Moorthy B; Sriram P; Pathak DN; Bodell WJ; Randerath K
Cancer Res; 1996 Jan; 56(1):53-7. PubMed ID: 8548775
[TBL] [Abstract][Full Text] [Related]
18. Genotoxic mechanism of tamoxifen in developing endometrial cancer.
Kim SY; Suzuki N; Laxmi YR; Shibutani S
Drug Metab Rev; 2004 May; 36(2):199-218. PubMed ID: 15237851
[TBL] [Abstract][Full Text] [Related]
19. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.
Hellmann-Blumberg U; Taras TL; Wurz GT; DeGregorio MW
Breast Cancer Res Treat; 2000 Mar; 60(1):63-70. PubMed ID: 10845810
[TBL] [Abstract][Full Text] [Related]
20. Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology.
Mahadevan B; Arora V; Schild LJ; Keshava C; Cate ML; Iversen PL; Poirier MC; Weston A; Pereira C; Baird WM
Mol Carcinog; 2006 Feb; 45(2):118-25. PubMed ID: 16329150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
